ARA-290 vs Semax
Both ARA-290 and Semax are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
ARA-290
Evidence BARA-290 (Cibinetide)
An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
View full ARA-290 profile →Semax
Evidence BSemax (MEHFPGP)
A synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
View full Semax profile →Side-by-Side
| Attribute | ARA-290 | Semax |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy | Not FDA-approved in US — approved in Russia for stroke and cognitive disorders |
| Typical Dose | Trial range: 1–4 mg subcutaneous daily | 200–600 mcg intranasal, morning |
| Clinics Indexed | 9 | 89 |
| Categories | anti-inflammatory, neuroprotection | cognitive, neuroprotection |
Key reported benefits — ARA-290
- ✓Small-fiber neuropathy improvement
- ✓Anti-inflammatory
- ✓No erythrocytosis
Key reported benefits — Semax
- ✓BDNF increase
- ✓Enhanced focus
- ✓Memory improvement
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.